FDA clears Biobeat’s remote vital sign monitoring system

[Image from Biobeat]Biobeat announced today that it received FDA 510(k) clearance for its wearable remote patient monitoring device.

FDA clearance allows the wearable device to monitor respiratory rate and body temperature in addition to cuffless blood pressure, blood oxygen saturation and pulse rate.

Petah Tikva, Israel-based Biobeat’s wireless wrist and chest monitoring devices became the first of their kind to receive FDA clearance for cuffless blood pressure monitoring from photoplethysmography (PPG) only in 2019. The platform can support health teams by transmitting real-time patient data, according to a news release.

The system uses proprietary, non-invasive reflective PPG monitoring technology to automatically and continuously track multiple vital signs and health parameters. It connects to a cloud-based patient management system that provides real-time data and alerts.

Biobeat’s system includes an automated, customizable early war…

Read more
  • 0

Remote patient monitoring poised for further growth in clinical trials 

Remote patient monitoring technology from Biobeat can detect 14 cardio-pulmonary vital sign measurements. A number of pharma companies and contract research organizations are implementing the technology. Image courtesy of Biobeat.

Remote patient monitoring (RPM) is among the trends that will have the greatest impact on the pharma sector in 2021, according to the recent report, “The State of the Biopharmaceutical Industry, 2021 Edition,” from GlobalData. After a period of gradual uptake, RPM “witnessed a massive uptake in the life-sciences sector in 2020,” according to the GlobalData report.

The technology offers several advantages. It can help pharmaceutical companies continue making progress with clinical trials during a pandemic. The ability to gather data from patients remotely can also reduce the burden on medical staff while reducing gaps in clinical trial data. “One of the advantages when you have freq…

Read more
  • 0